Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells

Sang Man Jin, Hye Won Jang, Seo Young Sohn, Na Kyung Kim, Ji Young Joung, Yoon Young Cho, Sun Wook Kim, Jae Hoon Chung

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Current alternative therapies for refractory thyroid cancer such as kinase inhibitors have limitations including incomplete response and toxicity. Although tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce cancer cell-specific apoptosis, various degrees of TRAIL resistance have been reported for different types of thyroid cancer cells. Here, we investigated if modulation of autophagy could improve sensitivity to TRAIL in papillary and anaplastic thyroid cancer cells. Human papillary thyroid cancer cells (TPC-1 cells) and human anaplastic thyroid cancer cells (FRO cells) were treated with TRAIL after transfection with ATG7 siRNA or control siRNA. Levels of autophagy and apoptosis were confirmed by Western blot of ATG7, LC3, caspase-3 and poly (ADP-ribose) polymerase. Viability index was determined by dimethyl-thiazole- diphenyltetrazolium bromide assay. Fraction of apoptotic cells was determined by flow cytometry. In TPC-1 cells, treatment with TRAIL increased the levels of autophagy. A low concentration (20 ng/ml) of TRAIL resulted in significantly decreased viability index and increased apoptosis. However, inhibition of autophagy with ATG7 siRNA desensitised the cells to TRAIL-induced apoptosis. In FRO cells, TRAIL did not increase the levels of autophagy. In contrast to TPC-1 cells, inhibition of autophagy with ATG7 siRNA sensitised FRO cells to TRAIL-induced apoptosis. Autophagy might contribute to the known sensitivity of papillary thyroid cancer cells to TRAIL-induced apoptosis. Inhibition of autophagy in anaplastic thyroid cancer cells could sensitise these cells to TRAIL-induced apoptosis.

Original languageEnglish
Pages (from-to)256-262
Number of pages7
JournalEndocrine
Volume45
Issue number2
DOIs
StatePublished - 2014 Mar 1

Fingerprint

Autophagy
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Small Interfering RNA
Anaplastic Thyroid Carcinoma
Papillary Thyroid cancer
Thyroid Neoplasms
Thiazoles
Poly(ADP-ribose) Polymerases
Complementary Therapies
Bromides
Caspase 3
Transfection

Keywords

  • Apoptosis
  • Autophagy
  • TRAIL
  • Thyroid cancer

Cite this

Jin, Sang Man ; Jang, Hye Won ; Sohn, Seo Young ; Kim, Na Kyung ; Joung, Ji Young ; Cho, Yoon Young ; Kim, Sun Wook ; Chung, Jae Hoon. / Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells. In: Endocrine. 2014 ; Vol. 45, No. 2. pp. 256-262.
@article{811950050f5e4cea9aaa497957bf801c,
title = "Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells",
abstract = "Current alternative therapies for refractory thyroid cancer such as kinase inhibitors have limitations including incomplete response and toxicity. Although tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce cancer cell-specific apoptosis, various degrees of TRAIL resistance have been reported for different types of thyroid cancer cells. Here, we investigated if modulation of autophagy could improve sensitivity to TRAIL in papillary and anaplastic thyroid cancer cells. Human papillary thyroid cancer cells (TPC-1 cells) and human anaplastic thyroid cancer cells (FRO cells) were treated with TRAIL after transfection with ATG7 siRNA or control siRNA. Levels of autophagy and apoptosis were confirmed by Western blot of ATG7, LC3, caspase-3 and poly (ADP-ribose) polymerase. Viability index was determined by dimethyl-thiazole- diphenyltetrazolium bromide assay. Fraction of apoptotic cells was determined by flow cytometry. In TPC-1 cells, treatment with TRAIL increased the levels of autophagy. A low concentration (20 ng/ml) of TRAIL resulted in significantly decreased viability index and increased apoptosis. However, inhibition of autophagy with ATG7 siRNA desensitised the cells to TRAIL-induced apoptosis. In FRO cells, TRAIL did not increase the levels of autophagy. In contrast to TPC-1 cells, inhibition of autophagy with ATG7 siRNA sensitised FRO cells to TRAIL-induced apoptosis. Autophagy might contribute to the known sensitivity of papillary thyroid cancer cells to TRAIL-induced apoptosis. Inhibition of autophagy in anaplastic thyroid cancer cells could sensitise these cells to TRAIL-induced apoptosis.",
keywords = "Apoptosis, Autophagy, TRAIL, Thyroid cancer",
author = "Jin, {Sang Man} and Jang, {Hye Won} and Sohn, {Seo Young} and Kim, {Na Kyung} and Joung, {Ji Young} and Cho, {Yoon Young} and Kim, {Sun Wook} and Chung, {Jae Hoon}",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/s12020-013-9997-8",
language = "English",
volume = "45",
pages = "256--262",
journal = "Endocrine",
issn = "1355-008X",
number = "2",

}

Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells. / Jin, Sang Man; Jang, Hye Won; Sohn, Seo Young; Kim, Na Kyung; Joung, Ji Young; Cho, Yoon Young; Kim, Sun Wook; Chung, Jae Hoon.

In: Endocrine, Vol. 45, No. 2, 01.03.2014, p. 256-262.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells

AU - Jin, Sang Man

AU - Jang, Hye Won

AU - Sohn, Seo Young

AU - Kim, Na Kyung

AU - Joung, Ji Young

AU - Cho, Yoon Young

AU - Kim, Sun Wook

AU - Chung, Jae Hoon

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Current alternative therapies for refractory thyroid cancer such as kinase inhibitors have limitations including incomplete response and toxicity. Although tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce cancer cell-specific apoptosis, various degrees of TRAIL resistance have been reported for different types of thyroid cancer cells. Here, we investigated if modulation of autophagy could improve sensitivity to TRAIL in papillary and anaplastic thyroid cancer cells. Human papillary thyroid cancer cells (TPC-1 cells) and human anaplastic thyroid cancer cells (FRO cells) were treated with TRAIL after transfection with ATG7 siRNA or control siRNA. Levels of autophagy and apoptosis were confirmed by Western blot of ATG7, LC3, caspase-3 and poly (ADP-ribose) polymerase. Viability index was determined by dimethyl-thiazole- diphenyltetrazolium bromide assay. Fraction of apoptotic cells was determined by flow cytometry. In TPC-1 cells, treatment with TRAIL increased the levels of autophagy. A low concentration (20 ng/ml) of TRAIL resulted in significantly decreased viability index and increased apoptosis. However, inhibition of autophagy with ATG7 siRNA desensitised the cells to TRAIL-induced apoptosis. In FRO cells, TRAIL did not increase the levels of autophagy. In contrast to TPC-1 cells, inhibition of autophagy with ATG7 siRNA sensitised FRO cells to TRAIL-induced apoptosis. Autophagy might contribute to the known sensitivity of papillary thyroid cancer cells to TRAIL-induced apoptosis. Inhibition of autophagy in anaplastic thyroid cancer cells could sensitise these cells to TRAIL-induced apoptosis.

AB - Current alternative therapies for refractory thyroid cancer such as kinase inhibitors have limitations including incomplete response and toxicity. Although tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce cancer cell-specific apoptosis, various degrees of TRAIL resistance have been reported for different types of thyroid cancer cells. Here, we investigated if modulation of autophagy could improve sensitivity to TRAIL in papillary and anaplastic thyroid cancer cells. Human papillary thyroid cancer cells (TPC-1 cells) and human anaplastic thyroid cancer cells (FRO cells) were treated with TRAIL after transfection with ATG7 siRNA or control siRNA. Levels of autophagy and apoptosis were confirmed by Western blot of ATG7, LC3, caspase-3 and poly (ADP-ribose) polymerase. Viability index was determined by dimethyl-thiazole- diphenyltetrazolium bromide assay. Fraction of apoptotic cells was determined by flow cytometry. In TPC-1 cells, treatment with TRAIL increased the levels of autophagy. A low concentration (20 ng/ml) of TRAIL resulted in significantly decreased viability index and increased apoptosis. However, inhibition of autophagy with ATG7 siRNA desensitised the cells to TRAIL-induced apoptosis. In FRO cells, TRAIL did not increase the levels of autophagy. In contrast to TPC-1 cells, inhibition of autophagy with ATG7 siRNA sensitised FRO cells to TRAIL-induced apoptosis. Autophagy might contribute to the known sensitivity of papillary thyroid cancer cells to TRAIL-induced apoptosis. Inhibition of autophagy in anaplastic thyroid cancer cells could sensitise these cells to TRAIL-induced apoptosis.

KW - Apoptosis

KW - Autophagy

KW - TRAIL

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=84896689242&partnerID=8YFLogxK

U2 - 10.1007/s12020-013-9997-8

DO - 10.1007/s12020-013-9997-8

M3 - Article

C2 - 23821365

AN - SCOPUS:84896689242

VL - 45

SP - 256

EP - 262

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 2

ER -